{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T23:02:50Z","timestamp":1780354970943,"version":"3.54.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007048","name":"Mayo Foundation for Medical Education and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostaglandins &amp; Other Lipid Mediators"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.prostaglandins.2021.106563","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T17:03:09Z","timestamp":1621616589000},"page":"106563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Divergent PGD2 and leukotriene C4 metabolite excretion following aspirin therapy: Ten patients with systemic mastocytosis"],"prefix":"10.1016","volume":"155","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6830-2190","authenticated-orcid":false,"given":"Joseph H.","family":"Butterfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravinder J.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prostaglandins.2021.106563_bib0005","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/all.12668","article-title":"Urinary 11\u03b2-PGF2\u03b1 and N-methylhistamine correlate with bone marrow biopsy findings in mast cell disorders","volume":"70","author":"Divekar","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000503964","article-title":"Survey of mast cell mediator levels from patients presenting with symptoms of mast cell activation","volume":"181","author":"Butterfield","year":"2020","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0015","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jaip.2014.06.011","article-title":"Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11\u03b2-prostaglandin 2\u03b1","volume":"2","author":"Ravi","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0020","series-title":"Lipid Mediators of Hypersensitivity and Inflammation in Middleton\u2019s Allergy Principles & Practice","first-page":"203","author":"Peebles","year":"2009"},{"issue":"1","key":"10.1016\/j.prostaglandins.2021.106563_bib0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0952-3278(91)90138-U","article-title":"Leukotriene C4 formation by enriched human basophil preparations from normal and asthmatic subjects","volume":"44","author":"van der Donk","year":"1991","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0030","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000144042","article-title":"Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production","volume":"147","author":"Butterfield","year":"2008","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0035","series-title":"Middleton\u2019s Allergy Principles & Practice","first-page":"1619","article-title":"Antileukotriene therapy in asthma","author":"Wenzel","year":"2009"},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0040","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/01.CIR.85.1.230","article-title":"Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation","volume":"85","author":"Carry","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0045","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1365-2133.2001.03947.x","article-title":"Increased urinary leukotriene E4 excretion in patients with atopic dermatitis","volume":"144","author":"Hishinuma","year":"2001","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0050","first-page":"403","article-title":"Sherman PM Levels of peptidoleukotriene E4 are elevated in active Crohn\u2019s disease","volume":"20","author":"Kim","year":"1995","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0055","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.iac.2007.09.004","article-title":"Urinary leukotriene E4","volume":"27","author":"Rabinovitch","year":"2007","journal-title":"Immunol. Allergy Clin. N. Am."},{"issue":"4","key":"10.1016\/j.prostaglandins.2021.106563_bib0060","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1172\/JCI620","article-title":"Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin- intolerant asthma","volume":"101","author":"Cowbum","year":"1998","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.prostaglandins.2021.106563_bib0065","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1183\/09031936.93.05060693","article-title":"Urinary leukotriene E4 in bronchial asthma","volume":"5","author":"Smith","year":"1992","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0070","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0091-6749(99)70324-6","article-title":"Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses","volume":"104","author":"Daffern","year":"1999","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0075","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1164\/ajrccm\/143.5_Pt_1.1025","article-title":"Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects","volume":"143","author":"Christie","year":"1991","journal-title":"Am. Rev. Respir. Dis."},{"issue":"13-14","key":"10.1016\/j.prostaglandins.2021.106563_bib0080","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.clinbiochem.2016.02.007","article-title":"Analytical and clinical validation of an LC-MS\/MS method for urine leukotriene E4: a marker of systemic mastocytosis","volume":"49","author":"Lueke","year":"2016","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0085","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.prostaglandins.2021.106563_bib0090","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","article-title":"Advances in the Classification and treatment of Mastocytosis: current status and outlook toward the future","volume":"77","author":"Valent","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0095","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2222.2008.03104.x","article-title":"Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis","volume":"39","author":"Ono","year":"2009","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0100","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1016\/j.jaip.2020.02.021","article-title":"The utility of measuring metabolites of mast cell mediators in systemic mastocytosis and mast cell activation syndrome","volume":"8","author":"Butterfield","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"24","key":"10.1016\/j.prostaglandins.2021.106563_bib0105","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1056\/NEJM198012113032405","article-title":"Increased production of prostaglandin D2 in patients with systemic mastocytosis","volume":"303","author":"Roberts","year":"1980","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0110","first-page":"141","article-title":"Markedly increased synthesis of prostaglandin D2 in systemic mastocytosis","volume":"93","author":"Roberts","year":"1980","journal-title":"Trans. Assoc. Am. Physicians"},{"issue":"1","key":"10.1016\/j.prostaglandins.2021.106563_bib0115","first-page":"18","article-title":"The flush syndrome: an expression of systemic mastocytosis with increased prostaglandin D2 production","volume":"26","author":"Kootte","year":"1983","journal-title":"Neth. J. Med."},{"issue":"2 Pt 1","key":"10.1016\/j.prostaglandins.2021.106563_bib0120","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1161\/01.HYP.6.2.285","article-title":"Recurrent syncope due to systemic mastocytosis","volume":"6","author":"Roberts","year":"1984","journal-title":"Hypertension"},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0125","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/1523-1747.ep12606209","article-title":"Improved diagnosis of mastocytosis by measurement of the major urinary metabolite of prostaglandin D2","volume":"104","author":"Morrow","year":"1995","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"issue":"5","key":"10.1016\/j.prostaglandins.2021.106563_bib0130","doi-asserted-by":"crossref","first-page":"481","DOI":"10.4065\/70.5.481","article-title":"Aspirin idiosyncrasy in systemic mast cell disease: a new look at mediator release during aspirin desensitization","volume":"70","author":"Butterfield","year":"1995","journal-title":"Mayo Clin. Proc."},{"issue":"1","key":"10.1016\/j.prostaglandins.2021.106563_bib0135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0952-3278(91)90138-U","article-title":"Leukotriene C4 formation by enriched human basophil preparations from normal and asthmatic subjects","volume":"44","author":"van der Donk","year":"1991","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"issue":"2","key":"10.1016\/j.prostaglandins.2021.106563_bib0140","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.ajpath.2011.04.023","article-title":"Yokozeki H. FcepsilonRI, but not FcgammaR, signals induce prostaglandin D2 and E2 production from basophils","volume":"179","author":"Morrow","year":"2011","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.prostaglandins.2021.106563_bib0145","first-page":"1","article-title":"Systemic mastocytosis: management of an unusual case with histamine (H1 and H2) antagonists and cyclooxygenase inhibition","volume":"10","author":"Crawhall","year":"1987","journal-title":"Clin. Invest. Med."},{"issue":"8672","key":"10.1016\/j.prostaglandins.2021.106563_bib0150","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(89)91516-X","article-title":"Aspirin and systemic mastocytosis","volume":"2","author":"Lorcerie","year":"1989","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.prostaglandins.2021.106563_bib0155","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000144042","article-title":"Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production","volume":"147","author":"Butterfield","year":"2008","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0160","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.prostaglandins.2009.01.001","article-title":"Survey of aspirin administration in systemic mastocytosis","volume":"88","author":"Butterfield","year":"2009","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0165","first-page":"36","article-title":"Mastocytosis without urticaria pigmentosa: a frequently unrecognized cause of recurrent syncope","volume":"95","author":"Roberts","year":"1982","journal-title":"Trns Assoc. Am. Physicians"},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0170","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2332\/allergolint.11-RA-0403","article-title":"Aspirin- intolerant asthma (AIA) assessment using the urinary biomarkers, leukotriene E4 (LTE4) and prostaglandin D2 (PGD2) metabolites","volume":"61","author":"Higashi","year":"2012","journal-title":"Allergol. Int."},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0175","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1164\/ajrccm.151.5.7735581","article-title":"The effect of aspirin desensitization on urinary leukotriene E4 concentration in aspirin-sensitive asthma","volume":"151","author":"Nasser","year":"1995","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0180","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1067\/mai.2003.1387","article-title":"A controlled study of 9\u03b1, 11\u03b2-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with brochial asthma and healthy controls after aspirin challenge","volume":"111","author":"Bochenek","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0185","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/j.1398-9995.2001.00913.x","article-title":"Possible involvement of mast-cell activation in aspirin provocation of aspirin-induced asthma","volume":"56","author":"Mita","year":"2001","journal-title":"Allergy"},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0190","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaci.2014.07.031","article-title":"Prostaglandin D2: a dominant mediator of aspirin-exacerbated respiratory disease","volume":"135","author":"Cahill","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0195","first-page":"279","article-title":"Platelet activating factor-induced human eosinophil activation. Generation and release of cyclo-oxygenase metabolites in human blood eosinophils from asthmatics","volume":"78","author":"Kroegel","year":"1993","journal-title":"Immunology"},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0200","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.4049\/jimmunol.141.7.2413","article-title":"Transformation of prostaglandin D2 to isomeric prostaglandin F2 compounds by human eosinophils. A potential mast cell-eosinophil interaction","volume":"141","author":"Parsons","year":"1988","journal-title":"J. Immunol."},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0205","doi-asserted-by":"crossref","first-page":"7626","DOI":"10.1073\/pnas.80.24.7626","article-title":"Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: predominant production of leukotriene C4","volume":"80","author":"Weller","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0210","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1111\/j.1476-5381.1996.tb15598.x","article-title":"Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects","volume":"118","author":"Tenor","year":"1996","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0215","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM199009063231006","article-title":"Leukotrienes and other products of the 5- lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases","volume":"323","author":"Lewis","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0220","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.prostaglandins.2010.03.003","article-title":"Increased leukotriene E4excretion in systemic mastocytosis","volume":"92","author":"Butterfield","year":"2010","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0225","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000237133","article-title":"Cysteinyl leukotriene production in anaphylactic reactions","volume":"108","author":"Denzlinger","year":"1995","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0230","first-page":"469","article-title":"The measurement of leukotrienes in urine as diagnostic option in systemic mastocytosis","volume":"62","author":"Raithel","year":"2011","journal-title":"J. Physiol. Pharmacol."},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0235","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1164\/ajrccm.161.6.9907054","article-title":"Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals","volume":"161","author":"Lee","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0240","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1182\/blood.V81.2.352.352","article-title":"Stimulation of human myelopoiesis by leukotrienes B4 and C4: interactions with granulocyte-macrophage colony-stimulating factor","volume":"81","author":"Stenke","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0245","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jaci.2003.12.323","article-title":"Hypersensitivity to aspirin: common eicosanoid alterations in urticarial and asthma","volume":"113","author":"Mastalerz","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0250","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jaci.2006.07.024","article-title":"Clinical and pathologic perspectives on aspirin sensitivity and asthma","volume":"118","author":"Stevenson","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"issue":"4","key":"10.1016\/j.prostaglandins.2021.106563_bib0255","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1172\/JCI620","article-title":"Over expression of leukotrienes C4 synthease in bronchial biopsies from patients with aspirin- intolerant asthma","volume":"101","author":"Cowburn","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0260","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0091-6749(99)70324-6","article-title":"Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses","volume":"104","author":"Daffern","year":"1999","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0265","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.iac.2016.06.011","article-title":"Mechanisms of benefit with aspirin therapy in aspirin- exacerbated respiratory disease","volume":"36","author":"Hill","year":"2016","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"10.1016\/j.prostaglandins.2021.106563_bib0270","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.4049\/jimmunol.1500905","article-title":"Aspirin-exacerbated respiratory disease involves a cysteinyl leukotriene-driven IL-33-mediated mast cell activation pathway","volume":"195","author":"Liu","year":"2015","journal-title":"J. Immunol."}],"container-title":["Prostaglandins &amp; Other Lipid Mediators"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882321000381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882321000381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:02:00Z","timestamp":1761098520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098882321000381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":54,"alternative-id":["S1098882321000381"],"URL":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2021.106563","relation":{},"ISSN":["1098-8823"],"issn-type":[{"value":"1098-8823","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Divergent PGD2 and leukotriene C4 metabolite excretion following aspirin therapy: Ten patients with systemic mastocytosis","name":"articletitle","label":"Article Title"},{"value":"Prostaglandins & Other Lipid Mediators","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2021.106563","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106563"}}